Literature DB >> 12151869

Emerging concepts in the pathophysiology and treatment of obesity-associated hypertension.

Stefan Engeli1, Arya M Sharma.   

Abstract

The dramatic increase in the prevalence of obesity is a global phenomenon associated with increased risk of the development of cardiovascular and renal disease. Changes in renal structure and function that occur early in the development of obesity may lead to urine outflow obstruction and increased intrarenal pressure, mechanisms sufficient to shift the pressure-natriuresis relation to higher blood pressure levels. Another important alteration that may lead to hypertension with obesity is the increase in sympathetic nervous system activity. Several studies point to higher leptin levels associated with hypertension in humans, and animal data now convincingly suggest that leptin has direct central effects that increase sympathetic outflow to the kidneys, associated with increases in blood pressure. Although understanding of the pathophysiology of obesity-associated hypertension has made substantial progress during the past years, treatment of obese hypertensives remains largely empirical and clearly deserves to be addressed in larger randomized, controlled trials.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12151869     DOI: 10.1097/00001573-200207000-00006

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  8 in total

Review 1.  Sympathetic nervous system as a target for aging and obesity-related cardiovascular diseases.

Authors:  Priya Balasubramanian; Delton Hall; Madhan Subramanian
Journal:  Geroscience       Date:  2018-12-05       Impact factor: 7.713

Review 2.  The complex spectrum of forensic issues arising from obesity.

Authors:  Roger W Byard
Journal:  Forensic Sci Med Pathol       Date:  2012-03-01       Impact factor: 2.007

3.  Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome.

Authors:  Zeina A Al-Thanoon; Isam H Mahmood
Journal:  Oman Med J       Date:  2012-01

4.  Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice.

Authors:  Hiroaki Masuzaki; Hiroshi Yamamoto; Christopher J Kenyon; Joel K Elmquist; Nicholas M Morton; Janice M Paterson; Hiroshi Shinyama; Matthew G F Sharp; Stewart Fleming; John J Mullins; Jonathan R Seckl; Jeffrey S Flier
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

Review 5.  Management of arterial hypertension in obese patients.

Authors:  Ulrich O Wenzel; Christian Krebs
Journal:  Curr Hypertens Rep       Date:  2007-12       Impact factor: 5.369

6.  Thiamine attenuates the hypertension and metabolic abnormalities in CD36-defective SHR: uncoupling of glucose oxidation from cellular entry accompanied with enhanced protein O-GlcNAcylation in CD36 deficiency.

Authors:  Takao Tanaka; Koichi Sohmiya; Tatsuji Kono; Fumio Terasaki; Ryoichi Horie; Yasuhiko Ohkaru; Michiko Muramatsu; Shinji Takai; Mizuo Miyazaki; Yasushi Kitaura
Journal:  Mol Cell Biochem       Date:  2007-05       Impact factor: 3.842

7.  The adipose renin-angiotensin system modulates systemic markers of insulin sensitivity and activates the intrarenal renin-angiotensin system.

Authors:  Suyeon Kim; Morvarid Soltani-Bejnood; Annie Quignard-Boulange; Florence Massiera; Michele Teboul; Gerard Ailhaud; Jung Han Kim; Naima Moustaid-Moussa; Brynn H Voy
Journal:  J Biomed Biotechnol       Date:  2006

8.  Sex influences the effect of adiposity on arterial stiffness and renin-angiotensin aldosterone system activity in young adults.

Authors:  Cindy Z Kalenga; Sharanya Ramesh; Sandra M Dumanski; Jennifer M MacRae; Kara Nerenberg; Amy Metcalfe; Darlene Y Sola; Sofia B Ahmed
Journal:  Endocrinol Diabetes Metab       Date:  2021-12-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.